While the impact of BRAF V600E mutations on NSCLC prognosis or chemotherapy efficacy remains unclear, with some studies suggesting shorter PFS with platinum-based chemotherapy [97], this has not been universally supported [98] (Figure 2). This evidence concerns the gene BRAF and non-small cell lung carcinoma.